Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers



  Free Subscription

Articles published in Radiother Oncol

Retrieve available abstracts of 124 articles:
HTML format

Single Articles

    May 2020
  1. TINUSZ B, Soos A, Hegyi P, Sarlos P, et al
    Efficacy and safety of stenting and additional oncological treatment versus stenting alone in unresectable esophageal cancer: a meta-analysis and systematic review.
    Radiother Oncol. 2020 May 15. pii: S0167-8140(20)30268.
    PubMed     Abstract available

  2. ZSCHAECK S, Lock S, Hofheinz F, Zips D, et al
    Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
    Radiother Oncol. 2020 May 14. pii: S0167-8140(20)30275.
    PubMed     Abstract available

  3. TAO Y, Auperin A, Blanchard P, Alfonsi M, et al
    Concurrent cisplatin and Dose escalation with Intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
    Radiother Oncol. 2020 May 14. pii: S0167-8140(20)30274.
    PubMed     Abstract available

  4. AL-MAMGANI A, Kessels R, Verhoef CG, Navran A, et al
    Randomized controlled trial to identify the optimal radiotherapy scheme for palliative treatment of incurable head and neck squamous cell carcinoma.
    Radiother Oncol. 2020 May 14. pii: S0167-8140(20)30273.
    PubMed     Abstract available

    April 2020
  5. ANDERSON JL, Newman NB, Anderson C, Sherry AD, et al
    Mean cardiopulmonary dose and vertebral marrow dose differentially predict lineage-specific leukopenia kinetics during radiotherapy for esophageal cancer.
    Radiother Oncol. 2020 Apr 11. pii: S0167-8140(19)33508.
    PubMed     Abstract available

  6. ZHOU S, Huang H, Chen Q, Tan KS, et al
    Long-term defects of nasal epithelium barrier functions in patients with nasopharyngeal carcinoma post chemo-radiotherapy.
    Radiother Oncol. 2020;148:116-125.
    PubMed     Abstract available

  7. VAN RIJN-DEKKER MI, van den Bosch L, van den Hoek JGM, Bijl HP, et al
    Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy.
    Radiother Oncol. 2020;147:103-110.
    PubMed     Abstract available

  8. URBAN R, Godoy T, Olson R, Wu J, et al
    FDG-PET/CT scan assessment of response 12 weeks post radical radiotherapy in oropharynx head and neck cancer: The impact of p16 status.
    Radiother Oncol. 2020;148:14-20.
    PubMed     Abstract available

    March 2020
  9. DE VEIJ MESTDAGH PD, Walraven I, Vogel WV, Schreuder WH, et al
    SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: A potentially practice-changing approach.
    Radiother Oncol. 2020;147:56-63.
    PubMed     Abstract available

  10. FEI Z, Qiu X, Li Y, Huang Y, et al
    Selection of a high-level physician may help improve outcomes of nasopharyngeal carcinoma.
    Radiother Oncol. 2020;147:130-135.
    PubMed     Abstract available

  11. BOEKHOFF MR, Defize IL, Borggreve AS, Takahashi N, et al
    3-Dimensional target coverage assessment for MRI guided esophageal cancer radiotherapy.
    Radiother Oncol. 2020;147:1-7.
    PubMed     Abstract available

  12. BEDDOK A, Vela A, Calugaru V, Tessonnier T, et al
    Proton therapy for head and neck squamous cell carcinomas: A review of the physical and clinical challenges.
    Radiother Oncol. 2020;147:30-39.
    PubMed     Abstract available

  13. DE FELICE F, Polimeni A, Valentini V
    The impact of Coronavirus (COVID-19) on head and neck cancer patients' care.
    Radiother Oncol. 2020;147:84-85.

  14. XU C, Jin JY, Zhang M, Liu A, et al
    The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy.
    Radiother Oncol. 2020;146:180-186.
    PubMed     Abstract available

  15. SHARABIANI M, Clementel E, Andratschke N, Hurkmans C, et al
    Generalizability assessment of head and neck cancer NTCP models based on the TRIPOD criteria.
    Radiother Oncol. 2020;146:143-150.
    PubMed     Abstract available

    February 2020
  16. ZHAI TT, Langendijk JA, van Dijk LV, van der Schaaf A, et al
    Pre-treatment radiomic features predict individual lymph node failure for head and neck cancer patients.
    Radiother Oncol. 2020;146:58-65.
    PubMed     Abstract available

  17. FIETKAU R, Hecht M, Hofner B, Lubgan D, et al
    Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial.
    Radiother Oncol. 2020;144:209-217.
    PubMed     Abstract available

  18. SARAH D, Daan N, Frederic D, Jean-Francois D, et al
    Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome.
    Radiother Oncol. 2020 Feb 7. pii: S0167-8140(20)30017.
    PubMed     Abstract available

    January 2020
  19. LI WZ, Liu GY, Lin LF, Lv SH, et al
    MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it.
    Radiother Oncol. 2020;145:101-108.
    PubMed     Abstract available

    November 2019
  20. BHATTACHARYYA T, Koto M, Ikawa H, Hayashi K, et al
    Assessment of risk factors associated with development of oronasal fistula as a late complication after carbon-ion radiotherapy for head and neck cancer.
    Radiother Oncol. 2019;144:53-58.
    PubMed     Abstract available

    October 2019
  21. LEE JY, Kim YA, Kim HS, Back JH, et al
    Radiotherapy can increase the risk of ischemic cerebrovascular disease in head and neck cancer patients: A Korean population-based cohort study.
    Radiother Oncol. 2019 Oct 17. pii: S0167-8140(19)33114.
    PubMed     Abstract available

    September 2019
  22. YANG Z, Zhang X, Wang X, Zhu XR, et al
    Multiple-CT optimization: An adaptive optimization method to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers.
    Radiother Oncol. 2019 Sep 26. pii: S0167-8140(19)33094.
    PubMed     Abstract available

  23. ELBERS JBW, Al-Mamgani A, Tesseslaar MET, van den Brekel MWM, et al
    Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Radiother Oncol. 2019 Sep 26. pii: S0167-8140(19)33046.
    PubMed     Abstract available

  24. WANG J, Qing G, Ou X, Hu W, et al
    The impact of target dosimetry on patients' locoregional recurrence in nasopharyngeal carcinoma: A propensity score-matched analysis.
    Radiother Oncol. 2019 Sep 20. pii: S0167-8140(19)33074.
    PubMed     Abstract available

    August 2019
  25. CHAN RJ, Blades R, Jones L, Downer TR, et al
    A single-blind, randomised controlled trial of StrataXRT(R) - A silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer.
    Radiother Oncol. 2019 Aug 21. pii: S0167-8140(19)33004.
    PubMed     Abstract available

  26. KUBO N, Kubota Y, Kawamura H, Oike T, et al
    Dosimetric parameters predictive of nasolacrimal duct obstruction after carbon-ion radiotherapy for head and neck carcinoma.
    Radiother Oncol. 2019 Aug 19. pii: S0167-8140(19)33015.
    PubMed     Abstract available

  27. VAN DEN BOSCH S, Doornaert PAH, Dijkema T, Zwijnenburg EM, et al
    (18)F-FDG-PET/CT-based treatment planning for definitive (chemo)radiotherapy in patients with head and neck squamous cell carcinoma improves regional control and survival.
    Radiother Oncol. 2019 Aug 19. pii: S0167-8140(19)33018.
    PubMed     Abstract available

  28. HEUKELOM J, Kantor ME, Mohamed ASR, Elhalawani H, et al
    Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation.
    Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33027.
    PubMed     Abstract available

  29. ZHAN M, Zheng H, Yang Y, Xu T, et al
    Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.
    Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33024.
    PubMed     Abstract available

  30. RADES D, Narvaez CA, Splettstosser L, Domer C, et al
    A randomized trial (RAREST-01) comparing Mepitel(R) Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).
    Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33016.
    PubMed     Abstract available

    July 2019
  31. YU S, Zhang W, Ni W, Xiao Z, et al
    A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy.
    Radiother Oncol. 2019;140:159-166.
    PubMed     Abstract available

    June 2019
  32. CHOW JCH, Cheung KM, Au KH, Zee BCY, et al
    Radiation-induced hypoglossal nerve palsy after definitive radiotherapy for nasopharyngeal carcinoma: Clinical predictors and dose-toxicity relationship.
    Radiother Oncol. 2019;138:93-98.
    PubMed     Abstract available

  33. HUANG L, Zhang Y, Liu Y, Li H, et al
    Prognostic value of retropharyngeal lymph node metastasis laterality in nasopharyngeal carcinoma and a proposed modification to the UICC/AJCC N staging system.
    Radiother Oncol. 2019;140:90-97.
    PubMed     Abstract available

  34. MOAN JM, Amdal CD, Malinen E, Svestad JG, et al
    The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
    Radiother Oncol. 2019;140:54-61.
    PubMed     Abstract available

  35. BATES JE, Morris CG, Hitchcock KE, Dziegielewski PT, et al
    Locally advanced hypopharyngeal and laryngeal cancer: Influence of HPV status.
    Radiother Oncol. 2019;140:6-9.
    PubMed     Abstract available

    May 2019
  36. VAN DER VEEN J, Willems S, Deschuymer S, Robben D, et al
    Benefits of deep learning for delineation of organs at risk in head and neck cancer.
    Radiother Oncol. 2019;138:68-74.
    PubMed     Abstract available

  37. WILKIE JR, Mierzwa ML, Yao J, Eisbruch A, et al
    Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy.
    Radiother Oncol. 2019;137:167-174.
    PubMed     Abstract available

  38. KOIVUNORO H, Kankaanranta L, Seppala T, Haapaniemi A, et al
    Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival.
    Radiother Oncol. 2019;137:153-158.
    PubMed     Abstract available

  39. YAO JJ, Qi ZY, Liu ZG, Jiang GM, et al
    Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Radiother Oncol. 2019;137:137-144.
    PubMed     Abstract available

  40. GANJU RG, Morse R, Hoover A, TenNapel M, et al
    The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation.
    Radiother Oncol. 2019;137:117-124.
    PubMed     Abstract available

  41. LIU SL, Sun XS, Yan JJ, Chen QY, et al
    Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
    Radiother Oncol. 2019;137:83-94.
    PubMed     Abstract available

  42. BRENNER B, Purim O, Gordon N, Goshen-Lago T, et al
    The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial.
    Radiother Oncol. 2019;134:74-80.
    PubMed     Abstract available

  43. LI HJ, Hu YY, Huang L, Zhou J, et al
    Subclassification of skull-base invasion for nasopharyngeal carcinoma using cluster, network and survival analyses: A double-center retrospective investigation.
    Radiother Oncol. 2019;134:37-43.
    PubMed     Abstract available

  44. GABANI P, Lin AJ, Barnes J, Oppelt P, et al
    Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.
    Radiother Oncol. 2019;134:81-88.
    PubMed     Abstract available

    April 2019
  45. VAN DER VEEN J, Gulyban A, Nuyts S
    Interobserver variability in delineation of target volumes in head and neck cancer.
    Radiother Oncol. 2019;137:9-15.
    PubMed     Abstract available

  46. MENECEUR S, Lock S, Gudziol V, Hering S, et al
    Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
    Radiother Oncol. 2019;137:24-31.
    PubMed     Abstract available

  47. ZHUO X, Huang X, Yan M, Li H, et al
    Comparison between high-dose and low-dose intravenous methylprednisolone therapy in patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2019;137:16-23.
    PubMed     Abstract available

  48. HAYASHI K, Koto M, Ikawa H, Hagiwara Y, et al
    Feasibility of Re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy.
    Radiother Oncol. 2019;136:148-153.
    PubMed     Abstract available

  49. WAGENAAR D, Kierkels RGJ, Free J, Langendijk JA, et al
    Composite minimax robust optimization of VMAT improves target coverage and reduces non-target dose in head and neck cancer patients.
    Radiother Oncol. 2019;136:71-77.
    PubMed     Abstract available

  50. DENG W, Xu C, Liu A, van Rossum PSN, et al
    The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy.
    Radiother Oncol. 2019;133:9-15.
    PubMed     Abstract available

  51. CHO WK, Oh D, Kim HK, Ahn YC, et al
    Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery.
    Radiother Oncol. 2019;133:87-92.
    PubMed     Abstract available

  52. LIAO W, Zheng Y, Bi S, Zhang B, et al
    Carotid stenosis prevalence after radiotherapy in nasopharyngeal carcinoma: A meta-analysis.
    Radiother Oncol. 2019;133:167-175.
    PubMed     Abstract available

  53. Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating.
    Radiother Oncol. 2019;133:35-42.
    PubMed     Abstract available

    March 2019
  54. KOSMIN M, Ledsam J, Romera-Paredes B, Mendes R, et al
    Rapid advances in auto-segmentation of organs at risk and target volumes in head and neck cancer.
    Radiother Oncol. 2019;135:130-140.
    PubMed     Abstract available

  55. SMITH J, Nastasi D, Tso R, Vangaveti V, et al
    The effects of continued smoking in head and neck cancer patients treated with radiotherapy: A systematic review and meta-analysis.
    Radiother Oncol. 2019;135:51-57.
    PubMed     Abstract available

  56. REID P, Marcu LG, Olver I, Moghaddasi L, et al
    Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response.
    Radiother Oncol. 2019;135:1-12.
    PubMed     Abstract available

  57. CAI J, Cheng J, Li H, Lin WJ, et al
    A nomogram for the prediction of cerebrovascular disease among patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2019;132:34-41.
    PubMed     Abstract available

    February 2019
  58. WAN Y, Tian L, Zhang G, Xin H, et al
    The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy.
    Radiother Oncol. 2019;131:35-44.
    PubMed     Abstract available

  59. MCDOWELL LJ, Ringash J, Xu W, Chan B, et al
    A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy.
    Radiother Oncol. 2019;131:179-185.
    PubMed     Abstract available

    January 2019
  60. GAWRYSZUK A, Bijl HP, Holwerda M, Halmos GB, et al
    Functional Swallowing Units (FSUs) as organs-at-risk for radiotherapy. PART 2: Advanced delineation guidelines for FSUs.
    Radiother Oncol. 2019;130:68-74.
    PubMed     Abstract available

  61. GAWRYSZUK A, Bijl HP, Holwerda M, Halmos GB, et al
    Functional Swallowing Units (FSUs) as organs-at-risk for radiotherapy. PART 1: Physiology and anatomy.
    Radiother Oncol. 2019;130:62-67.
    PubMed     Abstract available

  62. A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findi
    Radiother Oncol. 2019;130:46-55.
    PubMed     Abstract available

    November 2018
  63. YAO JJ, Zhang F, Gao TS, Zhang WJ, et al
    Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Radiother Oncol. 2018 Nov 14. pii: S0167-8140(18)33542.
    PubMed     Abstract available

  64. TOPKAN E, Yildirim BA
    Epoetin receptor status may alter the outcomes in head and neck cancers treated with radiotherapy and darbepoetin-alpha.
    Radiother Oncol. 2018 Nov 7. pii: S0167-8140(18)33397.

    October 2018
  65. LIANG SB, Zhang N, Chen DM, Yang XL, et al
    Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2018 Oct 23. pii: S0167-8140(18)33522.
    PubMed     Abstract available

  66. YILMAZ MT, Elmali A, Yazici G
    Comments on "High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer".
    Radiother Oncol. 2018 Oct 17. pii: S0167-8140(18)33506.

  67. KANAYAMA N, Kierkels RGJ, van der Schaaf A, Steenbakkers RJHM, et al
    External validation of a multifactorial normal tissue complication probability model for tube feeding dependence at 6months after definitive radiotherapy for head and neck cancer.
    Radiother Oncol. 2018 Oct 6. pii: S0167-8140(18)33496.
    PubMed     Abstract available

    September 2018
  68. HUANG XD, Zhou GQ, Lv JW, Zhou HQ, et al
    Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis.
    Radiother Oncol. 2018 Sep 27. pii: S0167-8140(18)33487.
    PubMed     Abstract available

  69. OVERGAARD J, Alsner J
    Effect of ESA as a modifier of radiotherapy in curative intended treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Radiother Oncol. 2018 Sep 21. pii: S0167-8140(18)33452.

  70. BIAU J, Dunet V, Lapeyre M, Simon C, et al
    Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers.
    Radiother Oncol. 2018 Sep 8. pii: S0167-8140(18)33458.
    PubMed     Abstract available

  71. KAMAL M, Mohamed ASR, Volpe S, Zaveri J, et al
    Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry.
    Radiother Oncol. 2018;128:442-451.
    PubMed     Abstract available

  72. DIXON L, Ramasamy S, Cardale K, Dyker K, et al
    Long term patient reported swallowing function following chemoradiotherapy for oropharyngeal carcinoma.
    Radiother Oncol. 2018;128:452-458.
    PubMed     Abstract available

    August 2018
  73. OU D, Adam J, Garberis I, Blanchard P, et al
    Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy.
    Radiother Oncol. 2018 Aug 29. pii: S0167-8140(18)33451.
    PubMed     Abstract available

  74. DE VEIJ MESTDAGH PD, Janssen T, Lamers E, Carbaat C, et al
    SPECT/CT-guided elective nodal irradiation for head and neck cancer: Estimation of clinical benefits using NTCP models.
    Radiother Oncol. 2018 Aug 4. pii: S0167-8140(18)33422.
    PubMed     Abstract available

  75. LEGER S, Zwanenburg A, Pilz K, Zschaeck S, et al
    CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer.
    Radiother Oncol. 2018 Aug 4. pii: S0167-8140(18)33419.
    PubMed     Abstract available

  76. LI YJ, Luo Y, Xie XQ, Li P, et al
    The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
    Radiother Oncol. 2018 Aug 3. pii: S0167-8140(18)33421.
    PubMed     Abstract available

    July 2018
  77. NOBLE DJ, Yeap PL, Seah SYK, Harrison K, et al
    Anatomical change during radiotherapy for head and neck cancer, and its effect on delivered dose to the spinal cord.
    Radiother Oncol. 2018 Jul 23. pii: S0167-8140(18)33396.
    PubMed     Abstract available

  78. VAN DEN BOSCH S, Dijkema T, Philippens MEP, Terhaard CHJ, et al
    Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of (18)F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting.
    Radiother Oncol. 2018 Jul 10. pii: S0167-8140(18)33352.
    PubMed     Abstract available

  79. NAVRAN A, Heemsbergen W, Janssen T, Hamming-Vrieze O, et al
    The impact of margin reduction on outcome and toxicity in head and neck cancer patients treated with image-guided volumetric modulated arc therapy (VMAT).
    Radiother Oncol. 2018 Jul 10. pii: S0167-8140(18)33347.
    PubMed     Abstract available

    May 2018
  80. TAO Y, Faivre L, Laprie A, Boisselier P, et al
    Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
    Radiother Oncol. 2018 May 18. pii: S0167-8140(18)30246.
    PubMed     Abstract available

  81. WINTER RM, Leibfarth S, Schmidt H, Zwirner K, et al
    Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients.
    Radiother Oncol. 2018 May 7. pii: S0167-8140(18)30209.
    PubMed     Abstract available

  82. MICHIELS S, Poels K, Crijns W, Delombaerde L, et al
    Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac.
    Radiother Oncol. 2018 May 5. pii: S0167-8140(18)30212.
    PubMed     Abstract available

  83. VAN DEN BOSCH S, Vogel WV, Raaijmakers CP, Dijkema T, et al
    Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: Radiotherapy target volume transformation and dose de-escalation.
    Radiother Oncol. 2018 May 3. pii: S0167-8140(18)30211.
    PubMed     Abstract available

  84. DELANEY AR, Dahele M, Slotman BJ, Verbakel WFAR, et al
    Is accurate contouring of salivary and swallowing structures necessary to spare them in head and neck VMAT plans?
    Radiother Oncol. 2018;127:190-196.
    PubMed     Abstract available

    April 2018
  85. MURTHY V, Lewis S, Kannan S, Khadanga CR, et al
    Submandibular function recovery after IMRT in head and neck cancer: A prospective dose modelling study.
    Radiother Oncol. 2018 Apr 30. pii: S0167-8140(18)30113.
    PubMed     Abstract available

  86. GREGOIRE V, Grau C
    In reply to "A Long-Awaited Guideline for the Delineation of Primary Tumor in Head and Neck Cancer, and a Few Concerns about It" by Sezin Yuce Sari et al.
    Radiother Oncol. 2018 Apr 27. pii: S0167-8140(18)30175.

  87. YUCE SARI S, Yeginer M, Cengiz M
    A long-awaited guideline for the delineation of primary tumor in head and neck cancer, and a few concerns about it.
    Radiother Oncol. 2018 Apr 24. pii: S0167-8140(18)30177.

    March 2018
  88. TAN TH, Soon YY, Cheo T, Ho F, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Radiother Oncol. 2018 Mar 16. pii: S0167-8140(18)30123.
    PubMed     Abstract available

  89. SHURYAK I, Hall EJ, Brenner DJ
    Dose dependence of accelerated repopulation in head and neck cancer: Supporting evidence and clinical implications.
    Radiother Oncol. 2018 Mar 10. pii: S0167-8140(18)30098.
    PubMed     Abstract available

  90. FANG P, Jiang W, Davuluri R, Xu C, et al
    High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
    Radiother Oncol. 2018 Mar 9. pii: S0167-8140(18)30117.
    PubMed     Abstract available

  91. OVERGAARD J, Hoff CM, Hansen HS, Specht L, et al
    DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Radiother Oncol. 2018 Mar 6. pii: S0167-8140(18)30105.
    PubMed     Abstract available

  92. HE J, Cai L, Chen Y, He Y, et al
    Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway.
    Radiother Oncol. 2018 Mar 5. pii: S0167-8140(18)30063.
    PubMed     Abstract available

    January 2018
  93. IQBAL MS, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A survey of UK national practice.
    Radiother Oncol. 2018 Jan 20. pii: S0167-8140(17)32734.

  94. SHAHID IQBAL M, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A systematic review.
    Radiother Oncol. 2018 Jan 19. pii: S0167-8140(17)32766.
    PubMed     Abstract available

  95. PAULINO AC, Mahajan A, Ye R, Grosshans DR, et al
    Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy.
    Radiother Oncol. 2018 Jan 17. pii: S0167-8140(18)30017.
    PubMed     Abstract available

  96. ADENIS A, Castan F, Conroy T
    Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32773.

  97. CHEN Y, Wang J
    Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery.
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32774.

  98. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Reply to Elicin et al.
    Radiother Oncol. 2018 Jan 4. pii: S0167-8140(17)32770.

  99. GREGOIRE V, Evans M, Le QT, Bourhis J, et al
    Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Onc
    Radiother Oncol. 2018;126:3-24.
    PubMed     Abstract available

  100. HANSEN CR, Johansen J, Samsoe E, Andersen E, et al
    Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy.
    Radiother Oncol. 2018;126:43-47.
    PubMed     Abstract available

  101. LASSEN P, Lacas B, Pignon JP, Trotti A, et al
    Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
    Radiother Oncol. 2018;126:107-115.
    PubMed     Abstract available

    December 2017
  102. ZHANG Y, Li WF, Liu X, Chen L, et al
    Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
    Radiother Oncol. 2017 Dec 16. pii: S0167-8140(17)32756.
    PubMed     Abstract available

  103. SHIRAISHI Y, Fang P, Xu C, Song J, et al
    Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
    Radiother Oncol. 2017 Dec 13. pii: S0167-8140(17)32751.
    PubMed     Abstract available

  104. KAMAL M, Rosenthal DI, Volpe S, Goepfert RP, et al
    Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.
    Radiother Oncol. 2017 Dec 8. pii: S0167-8140(17)32691.
    PubMed     Abstract available

    November 2017
  105. LEE AW, Ng WT, Pan JJ, Poh SS, et al
    International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.
    Radiother Oncol. 2017 Nov 15. pii: S0167-8140(17)32686.
    PubMed     Abstract available

  106. BOGOWICZ M, Leijenaar RTH, Tanadini-Lang S, Riesterer O, et al
    Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models.
    Radiother Oncol. 2017 Nov 6. pii: S0167-8140(17)32663.
    PubMed     Abstract available

  107. TAKAHASHI N, Umezawa R, Takanami K, Yamamoto T, et al
    Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Nov 3. pii: S0167-8140(17)32659.
    PubMed     Abstract available

    October 2017
  108. CEREDA E, Cappello S, Colombo S, Klersy C, et al
    Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy.
    Radiother Oncol. 2017 Oct 27. pii: S0167-8140(17)32655.
    PubMed     Abstract available

  109. OU D, Garberis I, Adam J, Blanchard P, et al
    Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
    Radiother Oncol. 2017 Oct 24. pii: S0167-8140(17)32647.
    PubMed     Abstract available

  110. DE-COLLE C, Menegakis A, Monnich D, Welz S, et al
    SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.
    Radiother Oncol. 2017 Oct 20. pii: S0167-8140(17)32648.
    PubMed     Abstract available

  111. RAO AD, Coquia S, De Jong R, Gourin C, et al
    Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers.
    Radiother Oncol. 2017 Oct 3. pii: S0167-8140(17)32584.
    PubMed     Abstract available

    September 2017
  112. MICHIELS S, Barragan AM, Souris K, Poels K, et al
    Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
    Radiother Oncol. 2017 Sep 23. pii: S0167-8140(17)32568.
    PubMed     Abstract available

  113. WOPKEN K, Bijl HP, Langendijk JA
    Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature.
    Radiother Oncol. 2017 Sep 21. pii: S0167-8140(17)32545.
    PubMed     Abstract available

  114. CHANG CL, Tsai HC, Lin WC, Chang JH, et al
    Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Sep 15. pii: S0167-8140(17)32548.
    PubMed     Abstract available

  115. SHIRAISHI Y, Xu C, Yang J, Komaki R, et al
    Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
    Radiother Oncol. 2017 Sep 13. pii: S0167-8140(17)32550.
    PubMed     Abstract available

    August 2017

  116. Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison.
    Radiother Oncol. 2017;124:232-239.
    PubMed     Abstract available

  117. MAVROIDIS P, Price A, Fried D, Kostich M, et al
    Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
    Radiother Oncol. 2017;124:240-247.
    PubMed     Abstract available

  118. GUTTMANN DM, Frick MA, Carmona R, Deville C Jr, et al
    A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma.
    Radiother Oncol. 2017;124:271-276.
    PubMed     Abstract available

    June 2017
  119. ZHANG W, Zhang X, Yang P, Blanchard P, et al
    Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer.
    Radiother Oncol. 2017;123:401-405.
    PubMed     Abstract available

  120. CHEN AM, Chin R, Beron P, Yoshizaki T, et al
    Inadequate target volume delineation and local-regional recurrence after intensity-modulated radiotherapy for human papillomavirus-positive oropharynx cancer.
    Radiother Oncol. 2017;123:412-418.
    PubMed     Abstract available

    April 2017
  121. WU B, Kusters M, Kunze-Busch M, Dijkema T, et al
    Cross-institutional knowledge-based planning (KBP) implementation and its performance comparison to Auto-Planning Engine (APE).
    Radiother Oncol. 2017;123:57-62.
    PubMed     Abstract available

    March 2017
  122. NAKAMURA N, Zenda S, Tahara M, Okano S, et al
    Proton beam therapy for olfactory neuroblastoma.
    Radiother Oncol. 2017;122:368-372.
    PubMed     Abstract available

    February 2017
  123. HAMMING-VRIEZE O, van Kranen SR, Heemsbergen WD, Lange CA, et al
    Analysis of GTV reduction during radiotherapy for oropharyngeal cancer: Implications for adaptive radiotherapy.
    Radiother Oncol. 2017;122:224-228.
    PubMed     Abstract available

  124. SODERSTROM K, Nilsson P, Laurell G, Zackrisson B, et al
    Dysphagia - Results from multivariable predictive modelling on aspiration from a subset of the ARTSCAN trial.
    Radiother Oncol. 2017;122:192-199.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Otorhinolaryngology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.